Abstract
Investigating the Risk of Hypertension After Initiation of Erenumab in the Post-Market Setting (S47.009)
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have